PDCD1 and non-small cell lung carcinoma: The KEYNOTE-024 study revealed that the PD-1 inhibitor pembrolizumab surpassed standard chemotherapy for NSCLC patients exhibiting a PD-L1 Tumor Proportion Score (TPS) of 50% [17].